Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease-Reference-Cited by-同舟云学术

Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease

Published:2014-05-22 Issue:6 Volume:10 Page:684-689
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Alexopoulos Panagiotis¹²,Kriett Laura³,Haller Bernhard⁴,Klupp Elisabeth³,Gray Katherine⁵,Grimmer Timo¹,Laskaris Nikolaos⁶,Förster Stefan³,Perneczky Robert¹⁷⁸,Kurz Alexander¹,Drzezga Alexander⁹,Fellgiebel Andreas¹⁰,Yakushev Igor³,

Affiliation:

1. Department of Psychiatry and PsychotherapyTechnische Universität MünchenMunichGermany

2. Department of PsychiatryUniversity of PatrasRion PatrasGreece

3. Department of Nuclear MedicineTechnische Universität MünchenMunichGermany

4. Institute of Medical Statistics and Epidemiology, Technische Universität MünchenMunichGermany

5. Biomedical Image Analysis Group, Department of ComputingImperial College LondonUK

6. Department of InformaticsAristotle University of ThessalonikiThessalonikiGreece

7. Neuroepidemiology and Ageing Research UnitSchool of Public Health, The Imperial College of ScienceTechnology and MedicineLondonUK

8. West London Cognitive Disorders Treatment and Research UnitWest London Mental Health TrustLondonUK

9. Department of Nuclear MedicineUniversity of CologneCologneGermany

10. Department of Psychiatry and PsychotherapyUniversity Medical Center of MainzMainzGermany

Funder

Alzheimer's Disease Neuroimaging Initiative

National Institutes of Health

DOD

National Institute on Aging

National Institute of Biomedical Imaging and Bioengineering

Alzheimer's Association

Alzheimer Drug Discovery Foundation

BioClinica, Inc

Biogen Idec

Bristol-Myers Squibb

Eisai Inc

Elan Pharmaceuticals, Inc

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Genentech

Innogenetics, N.V.

IXICO Ltd

Janssen Alzheimer Immunotherapy Research & Development, LLC

Johnson & Johnson Pharmaceutical Research & Development, LLC

Medpace, Inc

Merck & Co., Inc.

Meso Scale Diagnostics, LLC

NeuroRx Research

Novartis

Pfizer

Piramal Imaging

Servier

Synarc Inc

Takeda Pharmaceutical Company

Canadian Institutes of Health Research

Foundation for the National Institutes of Health

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2014.03.006

Reference21 articles.

1. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

2. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

3. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

4. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease

5. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42in humans

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease trajectories in older adults with non-AD pathologic change and comparison with Alzheimer’s disease pathophysiology: A longitudinal study;Neurobiology of Aging;2024-02

2. ATN profile classification across two independent prospective cohorts;Frontiers in Medicine;2023-07-25

3. How to use neuroimaging biomarkers in the diagnosis framework of neurodegenerative diseases?;Revue Neurologique;2022-05

4. The role of glucose in cognition, risk of dementia, and related biomarkers in individuals without type 2 diabetes mellitus or the metabolic syndrome: A systematic review of observational studies;Neuroscience & Biobehavioral Reviews;2022-04

5. Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline;Neurology;2022-02-02